PUBLICATIONS BY THE PARKINSON STUDY GROUP

JOURNAL ARTICLES, ABSTRACTS, LETTERS AND BOOK CHAPTERS


68. Parkinson Study Group (Holloway RG, primary author). Pramipexole vs. levodopa as initial treatment for Parkinson disease: A 4-year randomized controlled trial. *Arch Neurol* 2004;61:1044-1053.


143. Kang UJ and Auinger P on behalf of the Parkinson Study Group ELLDOPA Investigators. Activity enhances dopaminergic long-duration response in Parkinson disease. *Neurology* 2012;78:WNL.0b013e31824f8056


**ABSTRACTS**


223. Parkinson Study Group (Kieburtz K, primary author) and Nordic Study Group (NOMECOMT) (Rinne UK, primary author). The COMT inhibitor entacapone increases


274. Parkinson Study Group (S Fahn, presenter) Does levodopa slow or hasten the rate of progression of Parkinson disease? The results of the ELLDOPA trial. *Neurology* 2003;60:A80-81.


292. Pankratz N, Byder L, Halter CA, Rudolph A, Shults CW, Conneally PM, Foroud T, Nichols WC, Parkinson Study Group—PROGENI Investigators. A common non-synonymous SNP in the BR13 (ITM2C) gene accounts for a significant portion of the linkage evidence for Parkinson disease on chromosome 2q. Presented at The American Society of Human Genetics, October 25-29, 2005, Salt Lake City, UT. Available from: [http://www.ashg.org/cgi-bin/ashg05s/ashg05](http://www.ashg.org/cgi-bin/ashg05s/ashg05)


322. Peterson AL, Quinn JF, Horak FB, Nutt JG. The Relationship Between Balance, as Measured by Clinical Posturography, and Vitamin D in Parkinson’s Disease. *Mov Disord* 2010; (Suppl 7);S335-336.


333. Calleo, JS, Kunik M, Stanley, M, York M, Marsh, L. (2013). A Treatment Program for Anxiety and Depression in Parkinson Disease: A Pilot Study. In T. Barrera (Chair), Expanding the Reach of Anxiety Treatments in Late-life, Symposium presented at the annual meeting for the Anxiety and Depression Association of America, La Jolla, CA, April 6, 2013.


ANCILLARY STUDIES


PSG ANNUAL SYMPOSIA


9. Ninth Annual Symposium on Etiology, Pathogenesis and Treatment of Parkinson's Disease and Symposium on Hyperkinetic Movement Disorders. Co-sponsored by the


18. Eighteenth Annual Symposium on Etiology, Pathogenesis and Treatment of Parkinson’s Disease and Other Movement Disorders. Co-sponsored by the Parkinson Study Group,


25. Twenty Fifth Annual Symposium on Etiology, Pathogenesis and Treatment of Parkinson’s Disease and Other Movement Disorders. Presented by the Parkinson Study Group, Huntington Study Group, Dystonia Study Group, Myoclonus Study Group, Tourette’s Syndrome Study Group, Cooperative Ataxia Group, and Tremor Research


